{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T21:05:23Z","timestamp":1792098323810,"version":"4.4.0"},"reference-count":35,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2010,10,6]],"date-time":"2010-10-06T00:00:00Z","timestamp":1286323200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2011,4,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>A normal mineral metabolism is integral for skeletal development and preservation of bone integrity. Fibroblast growth factor 23 (FGF-23) is a bone-derived circulating factor that decreases serum concentrations of inorganic phosphorous (Pi) and 1,25-dihydroxyvitamin D3 [1,25(OH)2D3]. Increased FGF-23 expression is a direct or indirect culprit in several skeletal disorders; however, the relation between FGF-23 and fracture risk remains undetermined. We evaluated the prospective relation between serum intact FGF-23 (measured by a two-site monoclonal antibody ELISA) and fracture risk employing the Swedish part of the population-based Osteoporotic Fractures in Men Study (MrOS; n\u2009=\u20092868; mean age 75.4\u2009\u00b1\u20093.2 years; median follow-up period 3.35 years). The incidence of at least one validated fracture after baseline was 20.4 per 1000 person-years. FGF-23 was directly related to the overall fracture risk [age-adjusted hazard ratio (HR) per SD increase\u2009=\u20091.20, 95% confidence interval (CI) 1.03\u20131.40] and vertebral fracture risk (HR\u2009=\u20091.33, 95% CI 1.02\u20131.75). Spline models revealed a nonlinear relation between FGF-23 and fracture risk, with the strongest relation at FGF-23 levels above 55.7\u2009pg\/mL. FGF-23 levels above 55.7\u2009pg\/mL also were associated with an increased risk for hip and nonvertebral fractures (HR\u2009=\u20092.30, 95% CI 1.16\u20134.58, and HR\u2009=\u20091.63, 95% CI 1.01\u20132.63, respectively). These relations remained essentially unaltered after adjustment for bodymass index (BMI), bone mineral density (BMD), glomerular filtration rate, 25(OH)2D3, parathyroid hormone (PTH), and other fracture risk factors. In conclusion, FGF-23 is a novel predictor of fracture risk in elderly men. \u00a9 2011 American Society for Bone and Mineral Research.<\/jats:p>","DOI":"10.1002\/jbmr.263","type":"journal-article","created":{"date-parts":[[2010,10,6]],"date-time":"2010-10-06T20:46:49Z","timestamp":1286398009000},"page":"857-864","source":"Crossref","is-referenced-by-count":104,"title":["Serum fibroblast growth factor-23 (FGF-23) and fracture risk in elderly men"],"prefix":"10.1093","volume":"26","author":[{"given":"Majd AI","family":"Mirza","sequence":"first","affiliation":[{"name":"Department of Medical Sciences, Uppsala University Hospital, Uppsala, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magnus K","family":"Karlsson","sequence":"additional","affiliation":[{"name":"Clinical and Molecular Osteoporosis Research Unit, Department of Clinical Sciences and Orthopaedic Surgery, Lund University, Malm\u00f6 University Hospital, Malm\u00f6, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Mellstr\u00f6m","sequence":"additional","affiliation":[{"name":"Center for Bone Research at the Sahlgrenska Academy, Institute of Medicine, the Sahlgrenska Academy at G\u00f6teborg University, G\u00f6teborg, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Orwoll","sequence":"additional","affiliation":[{"name":"Oregon Health and Science University, Portland, OR, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claes","family":"Ohlsson","sequence":"additional","affiliation":[{"name":"Center for Bone Research at the Sahlgrenska Academy, Institute of Medicine, the Sahlgrenska Academy at G\u00f6teborg University, G\u00f6teborg, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00d6sten","family":"Ljunggren","sequence":"additional","affiliation":[{"name":"Department of Medical Sciences, Uppsala University Hospital, Uppsala, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tobias E","family":"Larsson","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Karolinska University Hospital, Stockholm, Sweden"},{"name":"Department of Clinical Science, Intervention and Technology, Karolinska Institutet, Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2010,10,6]]},"reference":[{"key":"2024020318070808000_bib1","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1172\/JCI18399","article-title":"FGF-23 in fibrous dysplasia of bone and its relationship to renal phosphate wasting","volume":"112","author":"Riminucci","year":"2003","journal-title":"J Clin Invest."},{"key":"2024020318070808000_bib2","doi-asserted-by":"crossref","first-page":"37419","DOI":"10.1074\/jbc.M304544200","article-title":"Regulation of fibroblastic growth factor 23 expression but not degradation by PHEX","volume":"278","author":"Liu","year":"2003","journal-title":"J Biol Chem."},{"key":"2024020318070808000_bib3","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1359\/JBMR.0301264","article-title":"FGF-23 is a potent regulator of vitamin D metabolism and phosphate homeostasis","volume":"19","author":"Shimada","year":"2004","journal-title":"J Bone Miner Res."},{"key":"2024020318070808000_bib4","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1038\/81664","article-title":"Autosomal dominant hypophosphataemic rickets is associated with mutations in FGF-23","volume":"26","year":"2000","journal-title":"Nat Genet."},{"key":"2024020318070808000_bib5","doi-asserted-by":"crossref","first-page":"6500","DOI":"10.1073\/pnas.101545198","article-title":"Cloning and characterization of FGF-23 as a causative factor of tumor-induced osteomalacia","volume":"98","author":"Shimada","year":"2001","journal-title":"Proc Natl Acad Sci USA."},{"key":"2024020318070808000_bib6","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.1056\/NEJMoa020881","article-title":"Fibroblast growth factor 23 in oncogenic osteomalacia and X-linked hypophosphatemia","volume":"348","author":"Jonsson","year":"2003","journal-title":"N Engl J Med."},{"key":"2024020318070808000_bib7","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1038\/ng1868","article-title":"DMP1 mutations in autosomal recessive hypophosphatemia implicate a bone matrix protein in the regulation of phosphate homeostasis","volume":"38","author":"Lorenz-Depiereux","year":"2006","journal-title":"Nat Genet."},{"key":"2024020318070808000_bib8","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1038\/ng1905","article-title":"Loss of DMP1 causes rickets and osteomalacia and identifies a role for osteocytes in mineral metabolism","volume":"38","author":"Feng","year":"2006","journal-title":"Nat Genet."},{"key":"2024020318070808000_bib9","doi-asserted-by":"crossref","first-page":"3087","DOI":"10.1210\/en.2003-1768","article-title":"Transgenic mice expressing fibroblast growth factor 23 under the control of the alpha1(I) collagen promoter exhibit growth retardation, osteomalacia, and disturbed phosphate homeostasis","volume":"145","author":"Larsson","year":"2004","journal-title":"Endocrinology."},{"key":"2024020318070808000_bib10","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.bbrc.2003.12.102","article-title":"FGF-23 transgenic mice demonstrate hypophosphatemic rickets with reduced expression of sodium phosphate cotransporter type IIa","volume":"314","author":"Shimada","year":"2004","journal-title":"Biochem Biophys Res Commun."},{"key":"2024020318070808000_bib11","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1007\/s00198-008-0780-2","article-title":"Relation between fibroblast growth factor-23, body weight and bone mineral density in elderly men","volume":"20","author":"Marsell","year":"2009","journal-title":"Osteoporos Int."},{"key":"2024020318070808000_bib12","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1359\/jbmr.080220","article-title":"Overexpression of fibroblast growth factor 23 suppresses osteoblast differentiation and matrix mineralization in vitro","volume":"23","author":"Wang","year":"2008","journal-title":"J Bone Miner Res."},{"key":"2024020318070808000_bib13","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1359\/jbmr.060110","article-title":"Free testosterone is an independent predictor of BMD and prevalent fractures in elderly men: MrOS Sweden","volume":"21","author":"Mellstrom","year":"2006","journal-title":"J Bone Miner Res."},{"key":"2024020318070808000_bib14","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/j.cct.2005.05.006","article-title":"Design and baseline characteristics of the osteoporotic fractures in men (MrOS) study\u2013a large observational study of the determinants of fracture in older men","volume":"26","author":"Orwoll","year":"2005","journal-title":"Contemp Clin Trials."},{"key":"2024020318070808000_bib15","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1359\/jbmr.080518","article-title":"Older men with low serum estradiol and high serum SHBG have an increased risk of fractures","volume":"23","author":"Mellstrom","year":"2008","journal-title":"J Bone Miner Res."},{"key":"2024020318070808000_bib16","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1080\/00365510601187773","article-title":"Evaluation of Gentian cystatin C reagent on Abbott Ci8200 and calculation of glomerular filtration rate expressed in mL\/min\/1.73 m(2) from the cystatin C values in mg\/L","volume":"67","author":"Flodin","year":"2007","journal-title":"Scand J Clin Lab Invest."},{"key":"2024020318070808000_bib17","doi-asserted-by":"crossref","first-page":"4957","DOI":"10.1210\/jc.2002-021105","article-title":"Increased circulatory level of biologically active full-length FGF-23 in patients with hypophosphatemic rickets\/osteomalacia","volume":"87","author":"Yamazaki","year":"2002","journal-title":"J Clin Endocrinol Metab."},{"key":"2024020318070808000_bib18","doi-asserted-by":"crossref","first-page":"2055","DOI":"10.1210\/jc.2005-2105","article-title":"Sensitivity of fibroblast growth factor 23 measurements in tumor-induced osteomalacia","volume":"91","author":"Imel","year":"2006","journal-title":"J Clin Endocrinol Metab."},{"key":"2024020318070808000_bib19","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1093\/oxfordjournals.aje.a009034","article-title":"Time-to-event analysis of longitudinal follow-up of a survey: choice of the time-scale","volume":"145","author":"Korn","year":"1997","journal-title":"Am J Epidemiol."},{"key":"2024020318070808000_bib20","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/S0169-2607(97)00043-6","article-title":"Gaining more flexibility in Cox proportional hazards regression models with cubic spline functions","volume":"54","author":"Heinzl","year":"1997","journal-title":"Comput Methods Programs Biomed."},{"key":"2024020318070808000_bib21","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1007\/s00198-007-0343-y","article-title":"The use of clinical risk factors enhances the performance of BMD in the prediction of hip and osteoporotic fractures in men and women","volume":"18","author":"Kanis","year":"2007","journal-title":"Osteoporos Int."},{"key":"2024020318070808000_bib22"},{"key":"2024020318070808000_bib23","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1038\/ng1095-130","article-title":"A gene (PEX) with homologies to endopeptidases is mutated in patients with X-linked hypophosphatemic rickets. The HYP Consortium","volume":"11","year":"1995","journal-title":"Nat Genet."},{"key":"2024020318070808000_bib24","doi-asserted-by":"crossref","first-page":"e1000154","DOI":"10.1371\/journal.pgen.1000154","article-title":"Genetic evidence of serum phosphate-independent functions of FGF-23 on bone","volume":"4","author":"Sitara","year":"2008","journal-title":"PLoS Genet."},{"key":"2024020318070808000_bib25","doi-asserted-by":"crossref","first-page":"2272","DOI":"10.1046\/j.1523-1755.2003.00328.x","article-title":"Circulating concentration of FGF-23 increases as renal function declines in patients with chronic kidney disease, but does not change in response to variation in phosphate intake in healthy volunteers","volume":"64","author":"Larsson","year":"2003","journal-title":"Kidney Int."},{"key":"2024020318070808000_bib26","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.atherosclerosis.2009.01.001","article-title":"Circulating fibroblast growth factor-23 is associated with vascular dysfunction in the community","volume":"205","author":"Mirza","year":"2009","journal-title":"Atherosclerosis."},{"key":"2024020318070808000_bib27","doi-asserted-by":"crossref","first-page":"3125","DOI":"10.1093\/ndt\/gfp205","article-title":"Relationship between circulating FGF-23 and total body atherosclerosis in the community","volume":"24","author":"Mirza","year":"2009","journal-title":"Nephrol Dial Transplant."},{"key":"2024020318070808000_bib28","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1016\/j.atherosclerosis.2009.05.013","article-title":"Serum intact FGF-23 associate with left ventricular mass, hypertrophy and geometry in an elderly population","volume":"207","author":"Mirza","year":"2009","journal-title":"Atherosclerosis."},{"key":"2024020318070808000_bib29","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1161\/CIRCULATIONAHA.108.844506","article-title":"Fibroblast growth factor 23 and left ventricular hypertrophy in chronic kidney disease","volume":"119","author":"Gutierrez","year":"2009","journal-title":"Circulation."},{"key":"2024020318070808000_bib30","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1038\/ki.2010.194","article-title":"FGF-23 and vascular dysfunction in patients with stage 3 and 4 chronic kidney disease","volume":"78","author":"Yilmaz","year":"2010","journal-title":"Kidney Int."},{"key":"2024020318070808000_bib31","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1056\/NEJMoa0706130","article-title":"Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis","volume":"359","author":"Gutierrez","year":"2008","journal-title":"N Engl J Med."},{"key":"2024020318070808000_bib32","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1093\/ndt\/gfn571","article-title":"Peripheral vascular calcification in long-haemodialysis patients: associated factors and survival consequences","volume":"24","author":"Jean","year":"2009","journal-title":"Nephrol Dial Transplant."},{"key":"2024020318070808000_bib33","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1038\/ki.1976.42","article-title":"Bone histology in incipient and advanced renal failure","volume":"9","author":"Malluche","year":"1976","journal-title":"Kidney Int."},{"key":"2024020318070808000_bib34","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1038\/ki.1990.187","article-title":"Renal bone disease 1990: an unmet challenge for the nephrologist","volume":"38","author":"Malluche","year":"1990","journal-title":"Kidney Int."},{"key":"2024020318070808000_bib35","doi-asserted-by":"crossref","first-page":"2205","DOI":"10.1681\/ASN.2005010052","article-title":"Fibroblast growth factor-23 mitigates hyperphosphatemia but accentuates calcitriol deficiency in chronic kidney disease","volume":"16","author":"Gutierrez","year":"2005","journal-title":"J Am Soc Nephrol."}],"container-title":["Journal of Bone and Mineral Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fjbmr.263","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/jbmr\/article-pdf\/26\/4\/857\/56558775\/263_ftp.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jbmr\/article-pdf\/26\/4\/857\/56558775\/263_ftp.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,13]],"date-time":"2024-03-13T14:54:53Z","timestamp":1710341693000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jbmr\/article\/26\/4\/857-864\/7598076"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,10,6]]},"references-count":35,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2010,10,6]]},"published-print":{"date-parts":[[2011,4,1]]}},"URL":"https:\/\/doi.org\/10.1002\/jbmr.263","relation":{},"ISSN":["0884-0431","1523-4681"],"issn-type":[{"value":"0884-0431","type":"print"},{"value":"1523-4681","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2011,4,1]]},"published":{"date-parts":[[2010,10,6]]}}}